Your browser doesn't support javascript.
loading
Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis.
Shedrawy, Jad; Henriksson, Martin; Hergens, Maria-Pia; Askling, H Helena.
Afiliación
  • Shedrawy J; Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden. Electronic address: jad.shedrawy@ki.se.
  • Henriksson M; Department of Medical and Health Sciences/Division of Health Care Analysis, Linköping University, Sweden.
  • Hergens MP; Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden; Department of Medicine/Division of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden; Department of Communicable Disease Control and Prevention, Stockholm County, Sweden.
  • Askling HH; Department of Medicine/Division of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden; Department of Communicable Disease Control and Prevention, Sörmland County, Sweden.
Vaccine ; 36(50): 7659-7665, 2018 Nov 29.
Article en En | MEDLINE | ID: mdl-30385058
BACKGROUND: The number of notified cases of Tick-Borne Encephalitis (TBE) in Sweden has been increasing the past years despite the increased use of TBE-vaccine not subsidized by the healthcare system. Stockholm County is a high endemic area and an earlier study has shown that low-income households have lower vaccination coverage even when they are at high risk. This paper aims to determine the cost-effectiveness of a publicly funded TBE vaccination program in Stockholm. METHODS: In three different cohorts with individuals aged 3, 40 or 50 years, long-term costs and health outcomes of an out-of-pocket strategy (53% of the cohort is vaccinated on their own expenses) and a structured vaccination program (full cohort is vaccinated covered by the publicly funded health care system), were estimated using a Markov model. The Markov model predicts the costs and effects in term of Quality-adjusted Life Years (QALYs) over a lifetime horizon using a third-party healthcare payer perspective. The primary results are presented as an incremental cost effectiveness ratio (ICER) indicating the additional cost required to achieve one additional QALY with the structured vaccination program. RESULTS: The results show that the structured vaccination program is associated with a gain in QALYs and increased costs compared with an out-of-pocket strategy. The calculated ICERs were 27 761, 99 527 and 160 827 SEK/QALY in cohorts of age 3, 40 and 50, respectively. The sensitivity analyses showed that the results are robust when varying different parameters. CONCLUSION: Given the setting of Stockholm county, this analysis shows a cost per QALY of a free vaccinations program, especially for children of 3 years old, below generally acceptable cost-effectiveness thresholds in Sweden.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / Análisis Costo-Beneficio / Programas de Inmunización / Encefalitis Transmitida por Garrapatas / Financiación Gubernamental Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Vaccine Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / Análisis Costo-Beneficio / Programas de Inmunización / Encefalitis Transmitida por Garrapatas / Financiación Gubernamental Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Vaccine Año: 2018 Tipo del documento: Article Pais de publicación: Países Bajos